The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Improved Biomarkers and Clinical Outcome Measures, 2017Dopamine Buffering Capacity Measured by phMRI as a Novel Biomarker of Disease Progression in Parkinson's Disease
Study Rationale:
This project will test a new idea for measuring the severity of Parkinson's disease (PD). The brain acts as if it can store each dose of levodopa (L DOPA) for a short period of time... -
Research Grant, 2017Improving Participation in Clinical Trials in Individuals with Atypical Parkinsonian Syndromes through Virtual Research Visits (ImPaCT-Atypical)
Objective/Rationale:
The Michael J. Fox Foundation's Fox Trial Finder is designed to facilitate and increase the participation of individuals with Parkinson's disease (PD) and degenerative... -
Therapeutic Pipeline Program, 2017Advancing Neuroprotective Protein Regulators Toward the Clinical Candidate Phase
Study Rationale:
Addex Pharmaceuticals has developed drug discovery tools that can be used to screen its small molecule compound library for positive allosteric modulators (protein regulators) of TrkB... -
Therapeutic Pipeline Program, 2017Protein Homeostasis and the Ubiquitination Pathway in Parkinson's Disease
Study Rationale:
Parkinson's disease (PD) involves accumulation of toxic proteins in cells in specific areas of the brain. These cells normally have protective mechanisms to remove these toxic... -
Research Grant, 2017Development of Analytic Tests to Use as Nilotinib Companion Diagnostics in Parkinson's Disease
Study Rationale:
Evidence suggests that increased activity of the c-abl protein in the brain may contribute to the development and progression of Parkinson's disease (PD). Nilotinib, a drug that... -
Research Grant, 2017White Blood Cell and Urine Collection in LRRK2 and GBA Mutation Carriers
Study Rationale:
Mutations in the LRRK2 and GBA genes increase the risk for Parkinson's disease (PD). The mechanism by which these mutations increase PD risk is unknown. One potential explanation may...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.